Skip to content
Wenlo
Sign in
← Markets

Quest Diagnostics Incorporated

Catherine T. Doherty (Executive Vice President) sells DGX shares

4DGXFiled Nov 5, 2026, 7:05 PM ET· Period Nov 3, 2026

AI-generated summary

Executive Vice President Catherine T. Doherty received 4,827 shares as a grant, exercised 22,105 shares for $2,692,499.53, and sold 22,105 shares for $5,482,442.39 at an average price of $248.02. After these transactions, the insider directly holds 71,949 shares. The exercise and sales were made under a Rule 10b5-1 trading plan.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Catherine T. Doherty · Executive Vice President

Rule 10b5-1 plan

DateTransactionSharesPriceValueHeld afterOwnership
Nov 3, 2026A · grantFootnotes F1+4,827$0.00$0.0071,949Direct
Nov 3, 2026M · exercise or conversion of a derivativeFootnotes F2+22,105$121.81$2,692,499.5394,054Direct
Nov 3, 2026S · open-market saleFootnotes F2, F3−3,818$245.45$937,135.3590,236Direct
Nov 3, 2026S · open-market saleFootnotes F2, F4−5,990$246.26$1,475,126.7584,246Direct
Nov 3, 2026S · open-market saleFootnotes F2, F5−1,151$246.98$284,278.0183,095Direct
Nov 3, 2026S · open-market saleFootnotes F2, F6−2,358$248.38$585,689.0080,737Direct
Nov 3, 2026S · open-market saleFootnotes F2, F7−3,004$249.40$749,208.1177,733Direct
Nov 3, 2026S · open-market saleFootnotes F2, F8−2,877$250.49$720,654.5574,856Direct
Nov 3, 2026S · open-market saleFootnotes F2, F9−2,907$251.24$730,350.6171,949Direct
Nov 3, 2026M · exercise or conversion of a derivativeNon-Qualifed Stock Option (right to buy)Footnotes F2, F11−22,105$121.81$2,692,499.530Direct
Footnotes
  1. F1 Represents an award of restricted stock units.
  2. F2 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
  3. F3 This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. F4 This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. F5 This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. F6 This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  7. F7 This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. F8 This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  9. F9 This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  10. F10 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
  11. F11 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024.

More DGX filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.